2-[1-(4-chlorophenyl)cyclopropylamino]-3-methoxy-5,6,7,8-tetrahydro-3H-pyrido[4,3-d]pyrimidin-4-one | 1256476-65-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2-[1-(4-chlorophenyl)cyclopropylamino]-3-methoxy-5,6,7,8-tetrahydro-3H-pyrido[4,3-d]pyrimidin-4-one
• 英文别名: 2-[[1-(4-Chlorophenyl)cyclopropyl]amino]-3-methoxy-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one
• CAS: 1256476-65-9
• 化学式: C₁₇H₁₉ClN₄O₂
• 分子量: 346.816
• InChiKey: SUGFUWAVQTWINP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS
  申请人：Takahashi Akira

  公开号：US20120065189A1

  公开（公告）日：2012-03-15

  The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R 1 and R 2 , each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R 3 represents a lower alkynyl group or the like; R 4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.

  本发明提供了一种新型杂环化合物。所述杂环化合物的通式（1）表示，其中，R1和R2各自独立地表示氢；苯基低烷基，其可以在苯环上和/或低烷基上具有选自低烷基等的取代基；或环状C3-C8烷基低烷基；或类似物；R3表示低炔基或类似物；R4表示苯基，其可以具有选自1,3,4-噁二唑基（例如，卤素）或选自吡啶基等杂环基的取代基；所述杂环基可以具有至少一个选自低烷氧基等的取代基或其盐。
• Albumin fusion proteins
  申请人：Human Genome Sciences, Inc.

  公开号：EP2275557A1

  公开（公告）日：2011-01-19

  The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

  本发明包括白蛋白融合蛋白。本发明还包括编码本发明白蛋白融合蛋白的核酸分子、含有这些核酸的载体、用这些核酸载体转化的宿主细胞，以及制造本发明白蛋白融合蛋白和使用这些核酸、载体和/或宿主细胞的方法。此外，本发明还包括包含白蛋白融合蛋白的药物组合物，以及使用本发明白蛋白融合蛋白治疗、预防或改善疾病、失调或病症的方法。
• Fusion proteins of albumin and erythropoietin
  申请人：Human Genome Sciences, Inc.

  公开号：EP2277888A2

  公开（公告）日：2011-01-26

  The present invention encompasses albumin fusion proteins, namely fusions of human serum albumin and erythropoiethin. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

  本发明包括白蛋白融合蛋白，即人血清白蛋白和红细胞生成素的融合蛋白。本发明还包括编码本发明白蛋白融合蛋白的核酸分子、含有这些核酸的载体、用这些核酸载体转化的宿主细胞，以及制造本发明白蛋白融合蛋白和使用这些核酸、载体和/或宿主细胞的方法。此外，本发明还包括包含白蛋白融合蛋白的药物组合物，以及使用本发明白蛋白融合蛋白治疗、预防或改善疾病、失调或病症的方法。
• Fusion proteins of albumin and interferon beta
  申请人：Human Genome Sciences, Inc.

  公开号：EP2277889A2

  公开（公告）日：2011-01-26

  The present invention encompasses albumin fusion proteins, namely fusions of human serum albumin and interferon beta. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

  本发明包括白蛋白融合蛋白，即人血清白蛋白和干扰素β的融合蛋白。本发明还包括编码本发明白蛋白融合蛋白的核酸分子、含有这些核酸的载体、用这些核酸载体转化的宿主细胞，以及制造本发明白蛋白融合蛋白和使用这些核酸、载体和/或宿主细胞的方法。此外，本发明还包括包含白蛋白融合蛋白的药物组合物，以及使用本发明白蛋白融合蛋白治疗、预防或改善疾病、失调或病症的方法。
• Albumin Fusion Proteins
  申请人：Rosen Craig A.

  公开号：US20110002888A1

  公开（公告）日：2011-01-06

  The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.